Shattuck Labs Q3 loss widens to $25.2 million; cash expected to last into 2029
Shattuck Labs reported a third-quarter 2026 net loss of $25.2 million, or $0.14 per share, up from $10.1 million a year earlier, as research and development spending rose to $21.6 million from $7.6 million. The company had no revenue in the quarter, compared with $1.0 million of related party license revenue a year earlier, and said its $196.3 million in cash, cash equivalents and short-term investments should fund operations into 2029.
Key points
- Net loss of $25.2 million, or $0.14 per share, for the quarter ended September 30, 2026, versus a net loss of $10.1 million, or $0.14 per share, a year earlier.
- R&D expenses were $21.6 million versus $7.6 million; there was no license revenue in Q3 2026 compared with $1.0 million in Q3 2025.
- Cash, cash equivalents and short-term investments were $196.3 million at September 30, 2026, versus $86.1 million a year earlier.
- RECEPTIVE-CD1 Phase 2b trial of SL-325 in Crohn's disease was initiated; RECEPTIVE-HS1 Phase 2 trial start is expected in Q4 2026.
The filing
Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on November 05, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.